News headlines about Retrophin (NASDAQ:RTRX) have been trending somewhat positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Retrophin earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 88 out of 100, meaning that recent news coverage is very likely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have impacted Accern’s analysis:
- Crunching the Numbers for Retrophin Inc (RTRX) – Hayden Business Journal (haydenbusinessjournal.com)
- Retrophin Inc (RTRX): A Look Behind The Numbers – FLBC News (flbcnews.com)
- Shkreli’s Delight and Crypto Karma (finance.yahoo.com)
- Shkreli sentence turns on antics, investor impact of crime (finance.yahoo.com)
- Retrophin, Inc. (RTRX) Raised to Hold at ValuEngine (americanbankingnews.com)
A number of research firms have commented on RTRX. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a research report on Friday. TheStreet raised Retrophin from a “d” rating to a “c-” rating in a research report on Friday, May 12th. Finally, Zacks Investment Research lowered Retrophin from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $32.25.
Retrophin (NASDAQ RTRX) traded down 0.81% on Tuesday, reaching $20.69. The company’s stock had a trading volume of 215,250 shares. The company’s market capitalization is $789.80 million. Retrophin has a one year low of $15.55 and a one year high of $24.57. The firm has a 50-day moving average of $19.64 and a 200-day moving average of $18.98.
ILLEGAL ACTIVITY NOTICE: This article was originally published by BBNS and is the property of of BBNS. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://baseballnewssource.com/markets/somewhat-positive-news-coverage-very-likely-to-impact-retrophin-rtrx-stock-price-updated-updated-updated/1197084.html.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with our FREE daily email newsletter.